1. M. Benetkiewicz, A. Idbaih, P. Y. Cousin, B. Boisselier, Y. Marie, E. Criniere, K. Hoang-Xuan, J. Y. Delattre, M. Sanson, and O. Delattre. NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas. PLoS ONE, 4(1):e4107, 2009. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Base Sequence, *Brain Neoplasms/genetics/metabolism, Chromosomes, Human, Pair 1/genetics, Chromosomes, Human, Pair 19/genetics, DNA Mutational Analysis, *Gene Rearrangement, Humans, Molecular Sequence Data, *Mutation, *Oligodendroglioma/genetics/metabolism, Oligonucleotide Array Sequence Analysis, Receptor, Notch2/*genetics/metabolism, *Translocation, Genetic.



2. B. Boisselier, Y. Marie, S. El Hallani, G. Kaloshi, A. Iershov, V. Kavsan, D. Psimaras, J. Thillet, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis. J Neurooncol, 94(2):169-72, 2009. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW]



3. F. Ducray, E. Criniere, A. Idbaih, K. Mokhtari, Y. Marie, S. Paris, S. Navarro, F. Laigle-Donadey, C. Dehais, J. Thillet, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. alpha-Internexin expression identifies 1p19q codeleted gliomas. Neurology, 72(2):156-61, 2009. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Brain Neoplasms/diagnosis/*genetics, Chromosomes, Human, Pair 1/*genetics, Chromosomes, Human, Pair 19/*genetics, DNA Mutational Analysis, Disease Progression, Gene Deletion, Genes, Genetic Predisposition to Disease/*genetics, Genetic Screening, Genotype, Glioma/diagnosis/*genetics, Humans, Intermediate Filament Proteins/*genetics, Mutation/genetics, Oligodendroglioma/diagnosis/genetics, Predictive Value of Tests, Prognosis.



4. F. Ducray, Y. Marie, and M. Sanson. IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360(21):2248;-author, 2009. Note: CommentLetterUnited States. [WWW] Keyword(s): Brain Neoplasms/*genetics, Gene Expression Profiling, Glioma/*genetics, Humans, Isocitrate Dehydrogenase/*genetics, *Mutation, Prognosis.



5. S. El Hallani, B. Boisselier, Y. Marie, S. Paris, A. Idbaih, C. Carpentier, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. TP53 mutations but no CHEK2 *1100DelC variant in familial gliomas. Cancer Genet Cytogenet, 188(2):126-8, 2009. Note: LetterUnited States. [WWW] Keyword(s): Family, Female, Genetic Variation, Germ-Line Mutation, Glioma/*genetics, Humans, Male, *Mutation, Protein-Serine-Threonine Kinases/*genetics, *Sequence Deletion, Tumor Suppressor Protein p53/*genetics.



6. S. El Hallani, F. Ducray, A. Idbaih, Y. Marie, B. Boisselier, C. Colin, F. Laigle-Donadey, M. Rodero, O. Chinot, J. Thillet, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology, 72(4):332-6, 2009. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Age Factors, Age of Onset, Aged, Aged, 80 and over, Codon/blood/*genetics, Female, Follow-Up Studies, Gene Frequency/genetics, Genetic Variation/genetics, Glioblastoma/blood/epidemiology/*genetics, Humans, Male, Middle Aged, Mutation/genetics, Polymorphism, Single Nucleotide/*genetics, Tumor Suppressor Protein p53/blood/*genetics, Young Adult.



7. S. Everhard, J. Tost, H. El Abdalaoui, E. Criniere, F. Busato, Y. Marie, I. G. Gut, M. Sanson, K. Mokhtari, F. Laigle-Donadey, K. Hoang-Xuan, J. Y. Delattre, and J. Thillet. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol, 11(4):348-56, 2009. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Brain Neoplasms/enzymology/*genetics/pathology, CpG Islands, *DNA Methylation, DNA Modification Methylases/*genetics/*metabolism, DNA Repair Enzymes/*genetics/*metabolism, *Gene Expression Regulation, Enzymologic, Genotype, Glioblastoma/enzymology/*genetics/pathology, Humans, Promoter Regions, Genetic/*genetics, Tumor Suppressor Proteins/*genetics/*metabolism.



8. A. Idbaih, J. Aimard, B. Boisselier, Y. Marie, S. Paris, E. Criniere, R. Carvalho Silva, F. Laigle-Donadey, A. Rousseau, K. Mokhtari, J. Thillet, M. Sanson, K. Hoang-Xuan, and J. Y. Delattre. Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathol Appl Neurobiol, 35(2):208-13, 2009. Note: Journal ArticleResearch Support, Non-U.S. Gov'tEngland. [WWW] Keyword(s): Age of Onset, Brain Neoplasms/chemistry/*genetics, DNA Mutational Analysis, Female, Gene Expression, Glioblastoma/chemistry/*genetics, Humans, Male, Mutation, Missense, Protein Structure, Quaternary, Protein Structure, Tertiary, Receptor, Epidermal Growth Factor/chemistry/*genetics, Sex Characteristics.



9. G. Kaloshi, R. Guillevin, N. Martin-Duverneuil, F. Laigle-Donadey, D. Psimaras, Y. Marie, K. Mokhtari, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri. Neurology, 73(6):445-9, 2009. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents/pharmacology/therapeutic use, Cell Movement/physiology, Cerebral Cortex/drug effects/*pathology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms, Neuroepithelial/*diagnosis/*drug therapy/mortality/pathology, Neuroglia/pathology, Predictive Value of Tests, Prognosis, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult.



10. M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire, F. Ducray, S. El Hallani, B. Boisselier, K. Mokhtari, K. Hoang-Xuan, and J. Y. Delattre. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol, 27(25):4150-4, 2009. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited Statesofficial journal of the American Society of Clinical Oncology. [WWW] Keyword(s): Adolescent, Adult, Aged, Aged, 80 and over, Brain Neoplasms/enzymology/*genetics/mortality/pathology/therapy, Codon, DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Disease-Free Survival, Female, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Glioma/enzymology/*genetics/mortality/pathology/therapy, Humans, Isocitrate Dehydrogenase/*genetics, Kaplan-Meiers Estimate, Male, Middle Aged, *Mutation, Neoplasm Staging, Promoter Regions, Genetic, Proportional Hazards Models, Risk Assessment, Time Factors, Treatment Outcome, Tumor Markers, Biological/*genetics, Tumor Suppressor Proteins/genetics, Young Adult.



11. S. Shete, F. J. Hosking, L. B. Robertson, S. E. Dobbins, M. Sanson, B. Malmer, M. Simon, Y. Marie, B. Boisselier, J. Y. Delattre, K. Hoang-Xuan, S. El Hallani, A. Idbaih, D. Zelenika, U. Andersson, R. Henriksson, A. T. Bergenheim, M. Feychting, S. Lonn, A. Ahlbom, J. Schramm, M. Linnebank, K. Hemminki, R. Kumar, S. J. Hepworth, A. Price, G. Armstrong, Y. Liu, X. Gu, R. Yu, C. Lau, M. Schoemaker, K. Muir, A. Swerdlow, M. Lathrop, M. Bondy, and R. S. Houlston. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet, 41(8):899-904, 2009. Note: 5R01 CA070917/CA/NCI NIH HHS/United States5R01 CA119215/CA/NCI NIH HHS/United StatesC1298/A8362/Cancer Research UK/United KingdomR01 CA119215/CA/NCI NIH HHS/United StatesWellcome Trust/United KingdomJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Alleles, *Genetic Predisposition to Disease, *Genome-Wide Association Study, Glioma/*genetics, Humans, Linkage Disequilibrium/genetics, Polymorphism, Single Nucleotide/genetics, Reproducibility of Results.



12. S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, C. Dehais, M. Sierra del Rio, Y. Meng, F. Laigle-Donadey, K. Hoang-Xuan, M. Sanson, and J. Y. Delattre. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology, 72(18):1601-6, 2009. Note: Journal ArticleUnited States. [WWW] Keyword(s): Adult, Aged, Angiogenesis Inhibitors/administration & dosage/adverse effects, Antibodies, Monoclonal/*administration & dosage/adverse effects, Antineoplastic Agents, Phytogenic/administration & dosage/adverse effects, Brain Neoplasms/*drug therapy/pathology/physiopathology, Camptothecin/administration & dosage/adverse effects/*analogs &, derivatives, Cerebral Hemorrhage/epidemiology, DNA Mutational Analysis, Female, Genetic Predisposition to Disease/genetics, Genetic Screening, Humans, Male, Middle Aged, Neoplasm Recurrence, Local/*drug therapy/prevention & control, Oligodendroglioma/*drug therapy/pathology/physiopathology, Patient Compliance, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult.



13. F. Ducray, A. Benouaich-Amiel, A. Idbaih, A. Rousseau, F. Laigle-Donadey, J. Y. Delattre, and M. Sanson. Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status. J Neurooncol, 88(2):185-8, 2008. Note: Case ReportsJournal ArticleNetherlands. [WWW] Keyword(s): Aged, Antineoplastic Agents, Alkylating/*therapeutic use, Brain Neoplasms/complications/*drug therapy/genetics/pathology, Chromosome Deletion, Chromosomes, Human, X/genetics, DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes/genetics, Dacarbazine/*analogs & derivatives/therapeutic use, Female, Glioblastoma/complications/*drug therapy/genetics/pathology, Humans, Tomography, X-Ray Computed, Tumor Suppressor Proteins/genetics.



14. F. Ducray, A. Idbaih, A. de Reynies, I. Bieche, J. Thillet, K. Mokhtari, S. Lair, Y. Marie, S. Paris, M. Vidaud, K. Hoang-Xuan, O. Delattre, J. Y. Delattre, and M. Sanson. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer, 7:41, 2008. Note: Journal ArticleEngland. [WWW]



15. A. Idbaih, B. Boisselier, Y. Marie, M. Sanson, S. El Hallani, E. Criniere, M. Fourtassi, S. Paris, C. Carpentier, A. Rousseau, K. Mokhtari, C. Combadiere, F. Laigle-Donadey, K. Hoang-Xuan, and J. Y. Delattre. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res, 1198:16-20, 2008. Note: Journal ArticleResearch Support, Non-U.S. Gov'tNetherlands. [WWW] Keyword(s): Adolescent, Adult, Age Factors, Aged, Brain Neoplasms/*genetics/metabolism/physiopathology, Chromosomes, Human, Pair 1/genetics, DNA Mutational Analysis, Female, Genetic Predisposition to Disease/*genetics, Genetic Screening, Genotype, Humans, Male, Middle Aged, Oligodendroglioma/*genetics/metabolism/physiopathology, Phenotype, Polymorphism, Single Nucleotide/*genetics, Prognosis, Proto-Oncogene Proteins c-mdm2/*genetics, Retrospective Studies, Survival Rate, Tumor Suppressor Protein p53/*genetics.



16. A. Idbaih, R. Carvalho Silva, E. Criniere, Y. Marie, C. Carpentier, B. Boisselier, S. Taillibert, A. Rousseau, K. Mokhtari, F. Ducray, J. Thillet, M. Sanson, K. Hoang-Xuan, and J. Y. Delattre. Genomic changes in progression of low-grade gliomas. J Neurooncol, 90(2):133-40, 2008. Note: Journal ArticleResearch Support, Non-U.S. Gov'tNetherlands. [WWW] Keyword(s): Adult, Chromosome Deletion, Chromosomes, Disease Progression, Female, Genome/*genetics, Glioma/*genetics/*metabolism, Humans, Male, Microsatellite Repeats, Middle Aged, Nucleic Acid Hybridization/methods.



17. A. Idbaih, E. Criniere, Y. Marie, A. Rousseau, K. Mokhtari, M. Kujas, Y. El Houfi, C. Carpentier, S. Paris, B. Boisselier, F. Laigle-Donadey, J. Thillet, M. Sanson, K. Hoang-Xuan, and J. Y. Delattre. Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. Neuro Oncol, 10(4):540-7, 2008. Note: Journal ArticleUnited States. [WWW]



18. A. Idbaih, Y. Marie, C. Lucchesi, G. Pierron, E. Manie, V. Raynal, V. Mosseri, K. Hoang-Xuan, M. Kujas, I. Brito, K. Mokhtari, M. Sanson, E. Barillot, A. Aurias, J. Y. Delattre, and O. Delattre. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer, 122(8):1778-86, 2008. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Astrocytoma/genetics/pathology, Brain Neoplasms/classification/*genetics/*pathology, *Chromosome Deletion, Chromosomes, Artificial, Bacterial, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 10, Chromosomes, Human, Pair 19, Chromosomes, Human, Pair 7, Chromosomes, Human, Pair 9, Disease-Free Survival, Female, Glioma/classification/*genetics/*pathology, Humans, Loss of Heterozygosity, Male, Middle Aged, Multivariate Analysis, Nucleic Acid Hybridization, Oligodendroglioma/genetics/pathology, Oligonucleotides, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Receptor, Epidermal Growth Factor/*genetics, Survival Analysis, World Health Organization.



19. A. Idbaih, S. Paris, B. Boisselier, Y. Marie, M. Sanson, J. Thillet, K. Hoang-Xuan, and J. Y. Delattre. Mutational analysis of Rac2 in gliomas. J Neurooncol, 87(3):365-6, 2008. Note: LetterResearch Support, Non-U.S. Gov'tNetherlands. [WWW]



20. G. Kaloshi, S. Everhard, F. Laigle-Donadey, Y. Marie, S. Navarro, K. Mokhtari, A. Idbaih, F. Ducray, J. Thillet, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology, 70(8):590-5, 2008. Note: Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Antineoplastic Agents, Alkylating/*therapeutic use, Chromosome Mapping, *Chromosomes, Human, Pair 19, Cohort Studies, DNA Mutational Analysis, Dacarbazine/*analogs & derivatives/therapeutic use, Disease-Free Survival, Female, Genetic Markers/physiology, Humans, Male, Middle Aged, Neoplasms, Neuroepithelial/*drug therapy/*genetics, O(6)-Methylguanine-DNA Methyltransferase/*metabolism, Prognosis, Retrospective Studies, Tumor Markers, Biological.



21. C. Soussain, K. Hoang-Xuan, L. Taillandier, E. Fourme, S. Choquet, F. Witz, O. Casasnovas, B. Dupriez, B. Souleau, A. L. Taksin, C. Gisselbrecht, A. Jaccard, A. Omuro, M. Sanson, M. Janvier, B. Kolb, J. M. Zini, and V. Leblond. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol, 26(15):2512-8, 2008. Note: Societe Francaise de Greffe de Moelle Osseuse-Therapie CellulaireClinical Trial, Phase IIJournal ArticleMulticenter StudyUnited Statesofficial journal of the American Society of Clinical Oncology. [WWW] Keyword(s): Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Brain Neoplasms/drug therapy/*therapy, Busulfan/administration & dosage, Combined Modality Therapy, Cyclophosphamide/administration & dosage, Cytarabine/administration & dosage, Etoposide/administration & dosage, Eye Neoplasms/drug therapy/*therapy, Female, *Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Large B-Cell, Diffuse/drug therapy/*therapy, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy/*therapy, Prospective Studies, *Salvage Therapy, Survival Rate, Thiotepa/administration & dosage.



22. S. Taillibert, R. Guillevin, C. Menuel, M. Sanson, K. Hoang-Xuan, J. Chiras, and H. Duffau. Brain lymphoma: usefulness of the magnetic resonance spectroscopy. J Neurooncol, 86(2):225-9, 2008. Note: Case ReportsJournal ArticleNetherlands. [WWW] Keyword(s): Adolescent, Antineoplastic Agents/therapeutic use, Brain Neoplasms/*diagnosis/drug therapy, Diagnosis, Differential, Encephalomyelitis/*diagnosis, Humans, Lymphoma, Non-Hodgkin/*diagnosis/drug therapy, *Magnetic Resonance Spectroscopy, Multiple Sclerosis/*diagnosis, Seizures/diagnosis, Treatment Outcome.



23. C. Carpentier, J. Lejeune, F. Gros, S. Everhard, Y. Marie, G. Kaloshi, F. Laigle-Donadey, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. Association of telomerase gene hTERT polymorphism and malignant gliomas. J Neurooncol, 84:249-253, 2007. Note: Journal article. [WWW]



24. E. Criniere, G. Kaloshi, F. Laigle-Donadey, J. Lejeune, N. Auger, A. Benouaich-Amiel, S. Everhard, K. Mokhtari, M. Polivka, J. Y. Delattre, K. Hoang-Xuan, J. Thillet, and M. Sanson. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol, 83:173-179, 2007. Note: Journal article. [WWW]



25. S. El Hallani, Y. Marie, A. Idbaih, M. Rodero, B. Boisselier, F. Laigle-Donadey, F. Ducray, J. Y. Delattre, and M. Sanson. No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J Neurooncol, 85(3):241-4, 2007. Note: Journal ArticleResearch Support, Non-U.S. Gov'tNetherlands. [WWW] Keyword(s): Adult, Aged, Aged, 80 and over, Brain Neoplasms/*genetics/mortality/pathology, Case-Control Studies, Female, Gene Expression Regulation, Neoplastic/genetics, Genetic Predisposition to Disease, Glioblastoma/*genetics/mortality/pathology, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Prognosis, Proto-Oncogene Proteins c-mdm2/*genetics, Reference Values, Risk Factors, Survival Analysis, Tumor Markers, Biological/*genetics.



26. A. Idbaih, B. Boisselier, M. Sanson, E. Criniere, S. Liva, Y. Marie, C. Carpentier, S. Paris, F. Laigle-Donadey, K. Mokhtari, M. Kujas, K. Hoang-Xuan, O. Delattre, and J. Y. Delattre. Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. Cancer Genet Cytogenet, 176(2):121-126, 2007. Note: Journal article. [WWW]



27. G. Kaloshi, A. Benouaich-Amiel, F. Diakite, S. Taillibert, J. Lejeune, F. Laigle-Donadey, M. A. Renard, W. Iraqi, A. Idbaih, S. Paris, L. Capelle, H. Duffau, P. Cornu, J. M. Simon, K. Mokhtari, M. Polivka, A. Omuro, A. Carpentier, M. Sanson, J. Y. Delattre, and K. Hoang-Xuan. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology, 68(21):1831-6, 2007. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Antineoplastic Agents, Alkylating/administration & dosage, Brain Neoplasms/*drug therapy/*genetics/physiopathology, *Chromosome Deletion, Chromosomes, Human, Pair 1/genetics, Chromosomes, Human, Pair 19/genetics, DNA Mutational Analysis, Dacarbazine/administration & dosage/*analogs & derivatives, Drug Resistance, Neoplasm/*genetics, Female, Gene Expression Regulation, Neoplastic/drug effects/genetics, Genetic Screening, Genotype, Glioma/*drug therapy/*genetics/physiopathology, Humans, Loss of Heterozygosity/genetics, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy/genetics, Retrospective Studies, Survival Rate, Treatment Outcome.



28. G. Kaloshi, K. Mokhtari, C. Carpentier, S. Taillibert, J. Lejeune, Y. Marie, J. Y. Delattre, R. Godbout, and M. Sanson. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol, 84:215-8, 2007. Note: Journal article. [WWW]



29. D. Ricard, G. Kaloshi, A. Amiel-Benouaich, J. Lejeune, Y. Marie, E. Mandonnet, M. Kujas, K. Mokhtari, S. Taillibert, F. Laigle-Donadey, A. F. Carpentier, A. Omuro, L. Capelle, H. Duffau, P. Cornu, R. Guillevin, M. Sanson, K. Hoang-Xuan, and J. Y. Delattre. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol, 61(5):484-90, 2007. Note: Journal ArticleUnited States. [WWW]



30. E. Vauleon, N. Auger, A. Benouaich-Amiel, F. Laigle-Donadey, G. Kaloshi, J. Lejeune, J. Y. Delattre, J. Thillet, and M. Sanson. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet, 172(1):33-7, 2007. Note: Journal ArticleUnited States. [WWW]



31. N. Auger, J. Thillet, K. Wanherdrick, A. Idbaih, M. E. Legrier, B. Dutrillaux, M. Sanson, and M. F. Poupon. Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther, 5(9):2182-92, 2006. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Antineoplastic Agents, Alkylating/pharmacokinetics/*pharmacology, Cell Line, Tumor, Dacarbazine/*analogs & derivatives/pharmacokinetics/pharmacology, Drug Resistance, Neoplasm/genetics, Gene Expression, Glioma/*drug therapy/*genetics/metabolism, Humans, In Situ Hybridization, Fluorescence/methods, Karyotyping/methods, O(6)-Methylguanine-DNA Methyltransferase/biosynthesis/genetics, RNA, Messenger/biosynthesis/genetics.



32. C. Carpentier, F. Laigle-Donadey, Y. Marie, N. Auger, A. Benouaich-Amiel, J. Lejeune, G. Kaloshi, J. Y. Delattre, J. Thillet, and M. Sanson. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology, 67(5):872-4, 2006. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Alleles, Chi-Square Distribution, Female, Follow-Up Studies, Gene Frequency, Glioblastoma/*genetics, Humans, Male, Middle Aged, Odds Ratio, *Polymorphism, Genetic, Promoter Regions (Genetics)/*genetics, Prospective Studies, RNA, Messenger/metabolism, Receptor, Epidermal Growth Factor/*genetics, Reverse Transcriptase Polymerase Chain Reaction/methods, Risk Factors, Sp1 Transcription Factor/*metabolism, Survival Analysis.



33. C. Dehais, F. Laigle-Donadey, Y. Marie, M. Kujas, J. Lejeune, A. Benouaich-Amiel, M. Pedretti, M. Polivka, K. H. Xuan, J. Thillet, J. Y. Delattre, and M. Sanson. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer, 107(8):1891-7, 2006. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Aged, 80 and over, Brain Neoplasms/*genetics/mortality, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 10, Chromosomes, Human, Pair 9, Disease-Free Survival, Female, Glioma/*genetics/mortality, Humans, Loss of Heterozygosity, Male, Middle Aged, Molecular Diagnostic Techniques, Prognosis, Receptor, Epidermal Growth Factor/genetics, Survival Analysis, Tumor Suppressor Protein p53/metabolism.



34. S. Everhard, G. Kaloshi, E. Criniere, A. Benouaich-Amiel, J. Lejeune, Y. Marie, M. Sanson, M. Kujas, K. Mokhtari, K. Hoang-Xuan, J. Y. Delattre, and J. Thillet. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol, 60(6):740-3, 2006. Note: Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Antineoplastic Agents, Alkylating/pharmacology/therapeutic use, Brain Neoplasms/diagnosis/*drug therapy/genetics, DNA Methylation/*drug effects, DNA Mutational Analysis, Dacarbazine/*analogs & derivatives/pharmacology/therapeutic use, Disease Progression, Female, Genetic Markers/drug effects/genetics, Glioma/diagnosis/*drug therapy/genetics, Humans, Male, Middle Aged, Neoadjuvant Therapy, Predictive Value of Tests, Prognosis, Promoter Regions (Genetics)/*drug effects/genetics, Survival Rate, Tumor Markers, Biological/*genetics, Tumor Suppressor Protein p14ARF/*genetics.



35. C. Houillier, J. Lejeune, A. Benouaich-Amiel, F. Laigle-Donadey, E. Criniere, K. Mokhtari, J. Thillet, J. Y. Delattre, K. Hoang-Xuan, and M. Sanson. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer, 106(10):2218-23, 2006. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Base Sequence, Brain Neoplasms/*genetics/*mortality/pathology, Disease Progression, Female, Gene Expression Regulation, Neoplastic, Genes, erbB-1/*genetics, Genetic Markers, Glioblastoma/*genetics/*mortality/pathology, Humans, Male, Middle Aged, Molecular Sequence Data, Multivariate Analysis, Neoplasm Staging, Polymerase Chain Reaction, Probability, Prognosis, Proportional Hazards Models, Proto-Oncogene Proteins c-mdm2/*genetics, Registries, Retrospective Studies, Risk Assessment, Sensitivity and Specificity, Survival Analysis.



36. F. Laigle-Donadey, E. Criniere, A. Benouaich, E. Lesueur, K. Mokhtari, K. Hoang-Xuan, and M. Sanson. Loss of 22q chromosome is related to glioma progression and loss of 10q. J Neurooncol, 76(3):265-8, 2006. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tNetherlands. [WWW] Keyword(s): Brain Neoplasms/*genetics/mortality/pathology, Chromosomes, Human, Pair 10, *Chromosomes, Human, Pair 22, Disease Progression, Genetic Markers, Glioma/*genetics/mortality/pathology, Humans, *Loss of Heterozygosity, Microsatellite Repeats, Reverse Transcriptase Polymerase Chain Reaction, Survival Analysis.



37. F. Laigle-Donadey and M. Sanson. [Pattern of care of high-grade gliomas]. Rev Prat, 56(16):1779-86, 2006. Note: Comparative StudyEnglish AbstractJournal ArticleReviewFrance. [WWW] Keyword(s): Adrenal Cortex Hormones/administration & dosage/therapeutic use, Adult, Age Factors, Aged, Anticonvulsants/therapeutic use, Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use, Brain/pathology, Brain Neoplasms/complications/diagnosis/drug, therapy/genetics/mortality/pathology/radiotherapy/surgery/*therapy, Combined Modality Therapy, Dacarbazine/administration & dosage/analogs & derivatives/therapeutic use, Epilepsy/prevention & control, Forecasting, Genetic Markers, Glioblastoma/drug therapy/radiotherapy, Glioma/complications/diagnosis/drug, therapy/genetics/mortality/pathology/radiography/radiotherapy/surgery/*the, rapy, Humans, Magnetic Resonance Imaging, Neoplasm Recurrence, Local/drug therapy, Oligodendroglioma/drug therapy, Prognosis, Quality of Life, Radiotherapy Dosage, Randomized Controlled Trials, Survival Analysis, Thromboembolism/prevention & control, Time Factors, Tomography, X-Ray Computed.



38. M. Sanson, F. Laigle-Donadey, and A. Benouaich-Amiel. Molecular changes in brain tumors: prognostic and therapeutic impact. Curr Opin Oncol, 18(6):623-30, 2006. Note: Journal ArticleUnited States. [WWW]



39. S. Taillibert, C. Chodkiewicz, F. Laigle-Donadey, M. Napolitano, S. Cartalat-Carel, and M. Sanson. Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol, 76(2):201-5, 2006. Note: Journal ArticleNetherlands. [WWW] Keyword(s): Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Brain Neoplasms/epidemiology/*pathology/therapy, Child, Child, Preschool, Combined Modality Therapy, Databases, Factual, Female, France/epidemiology, Humans, Infant, Karnofsky Performance Status, Male, Middle Aged, Neoplasms, Neuroepithelial/epidemiology/*pathology/therapy, Prognosis, Registries, Sex Factors, Survival Analysis, Tomography, X-Ray Computed.



40. M. J. van den Bent, A. F. Carpentier, A. A. Brandes, M. Sanson, M. J. Taphoorn, H. J. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, H. Haaxma-Reiche, J. M. Kros, M. C. van Kouwenhoven, C. J. Vecht, A. Allgeier, D. Lacombe, and T. Gorlia. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol, 24(18):2715-22, 2006. Note: Clinical Trial, Phase IIIJournal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tUnited Statesofficial journal of the American Society of Clinical Oncology. [WWW] Keyword(s): Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Brain Neoplasms/*drug therapy/genetics/radiotherapy, Chemotherapy, Adjuvant, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, Dose Fractionation, Female, Humans, Lomustine/therapeutic use, Loss of Heterozygosity, Male, Middle Aged, Oligodendroglioma/*drug therapy/genetics/radiotherapy, Procarbazine/therapeutic use, Survival Analysis, Vincristine/therapeutic use.



41. A. Idbaih, Y. Marie, G. Pierron, C. Brennetot, K. Hoang-Xuan, M. Kujas, K. Mokhtari, M. Sanson, J. Lejeune, A. Aurias, O. Delattre, and J. Y. Delattre. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol, 58(3):483-7, 2005. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Brain Neoplasms/classification/*genetics, *Chromosome Deletion, *Chromosomes, Human, Pair 1, Female, Gene Expression Profiling, Glioma/classification/*genetics, Humans, Loss of Heterozygosity, Male, Middle Aged.



42. M. Kujas, J. Lejeune, A. Benouaich-Amiel, E. Criniere, F. Laigle-Donadey, Y. Marie, K. Mokhtari, M. Polivka, M. Bernier, F. Chretien, A. Couvelard, L. Capelle, H. Duffau, P. Cornu, P. Broet, J. Thillet, A. F. Carpentier, M. Sanson, K. Hoang-Xuan, and J. Y. Delattre. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol, 58(2):322-6, 2005. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Brain Neoplasms/*genetics/pathology, *Chromosome Deletion, *Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, Female, Glioma/*genetics/pathology, Humans, Immunohistochemistry/methods, *Loss of Heterozygosity, Male, Middle Aged, Molecular Biology/methods.



43. F. Laigle-Donadey, A. Benouaich-Amiel, K. Hoang-Xuan, and M. Sanson. [Molecular biology of oligodendroglial tumors]. Neurochirurgie, 51(3-4 Pt 2):260-8, 2005. Note: English AbstractJournal ArticleReviewFrance. [WWW] Keyword(s): Brain Neoplasms/*genetics/*pathology, Chromosome Deletion, Chromosomes, Human, Pair 1/genetics, Chromosomes, Human, Pair 19/genetics, Cyclin-Dependent Kinase 4/genetics, Gene Expression Regulation, Neoplastic/*genetics, Genes, Tumor Suppressor, Glycoproteins/genetics, Humans, Loss of Heterozygosity/genetics, Molecular Biology/*methods, Oligodendroglioma/*genetics/*pathology, Phenotype, Point Mutation/*genetics, Proto-Oncogene Proteins c-mdm2/genetics.



44. Y. Marie, A. F. Carpentier, A. M. Omuro, M. Sanson, J. Thillet, K. Hoang-Xuan, and J. Y. Delattre. EGFR tyrosine kinase domain mutations in human gliomas. Neurology, 64(8):1444-5, 2005. Note: Journal ArticleUnited States. [WWW] Keyword(s): Astrocytoma/drug therapy/enzymology/genetics, Brain Neoplasms/drug therapy/*enzymology/*genetics, Carcinoma/drug therapy/enzymology/genetics, DNA Mutational Analysis, Drug Resistance, Neoplasm/genetics, Genetic Screening, Glioblastoma/drug therapy/enzymology/genetics, Glioma/drug therapy/*enzymology/*genetics, Humans, Lung Neoplasms/drug therapy/enzymology/genetics, Mutation/*genetics, Oligodendroglioma/drug therapy/enzymology/genetics, Protein Kinase Inhibitors/pharmacology/therapeutic use, Protein Structure, Tertiary/genetics, Quinazolines/pharmacology/therapeutic use, Receptor, Epidermal Growth Factor/*genetics.



45. K. Mokhtari, S. Paris, L. Aguirre-Cruz, N. Privat, E. Criniere, Y. Marie, J. J. Hauw, M. Kujas, D. Rowitch, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol, 31(1):62-9, 2005. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tEngland. [WWW] Keyword(s): Basic Helix-Loop-Helix Transcription Factors, Brain Neoplasms/*classification/metabolism/pathology, Chromosomes, Human, Pair 1, Glial Fibrillary Acidic Protein/*metabolism, Glioma/*classification/metabolism/pathology, Humans, Immunohistochemistry, Loss of Heterozygosity, Nerve Tissue Proteins/*metabolism, Tumor Suppressor Protein p53/*metabolism.



46. S. Taillibert, F. Laigle-Donadey, C. Chodkiewicz, M. Sanson, K. Hoang-Xuan, and J. Y. Delattre. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol, 75(1):85-99, 2005. Note: Journal ArticleReviewNetherlands. [WWW] Keyword(s): Breast Neoplasms/*pathology, Humans, Lung Neoplasms/*pathology, Meningeal Neoplasms/physiopathology/*secondary/therapy, Practice Guidelines.



47. L. Aguirre-Cruz, K. Mokhtari, K. Hoang-Xuan, Y. Marie, E. Criniere, S. Taillibert, M. Lopes, J. Y. Delattre, and M. Sanson. Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. J Neurooncol, 67(3):265-71, 2004. Note: Journal ArticleResearch Support, Non-U.S. Gov'tNetherlands. [WWW] Keyword(s): Astrocytes/metabolism, Basic Helix-Loop-Helix Transcription Factors, Brain Neoplasms/genetics/*metabolism/pathology, DNA Probes, DNA-Binding Proteins/genetics/*metabolism, Helix-Loop-Helix Motifs, Humans, In Situ Hybridization, Nerve Tissue Proteins/genetics/*metabolism, Neurons/metabolism, Oligodendroglia/metabolism.



48. C. Dichamp, S. Taillibert, L. Aguirre-Cruz, J. Lejeune, Y. Marie, M. Kujas, J. Y. Delattre, K. Hoang-Xuan, and M. Sanson. Loss of 14q chromosome in oligodendroglial and astrocytic tumors. J Neurooncol, 67(3):281-5, 2004. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tNetherlands. [WWW] Keyword(s): Astrocytoma/*genetics/pathology, Brain Neoplasms/*genetics/pathology, Chromosomes, Human, Pair 14/*genetics, DNA, Neoplasm/genetics, Genes, erbB-1/genetics, Genes, p16/physiology, Genes, p53/genetics, Humans, *Loss of Heterozygosity, Microsatellite Repeats, Neoplasm Staging, Oligodendroglioma/*genetics/pathology, Phosphoric Monoester Hydrolases/genetics, Survival Rate.



49. K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, A. F. Carpentier, F. Laigle, J. M. Simon, P. Cornu, P. Broet, M. Sanson, and J. Y. Delattre. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol, 22(15):3133-8, 2004. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited Statesofficial journal of the American Society of Clinical Oncology. [WWW] Keyword(s): Adult, Aged, Antineoplastic Agents, Alkylating/*therapeutic use, Astrocytoma/*drug therapy/*genetics, Brain Neoplasms/*drug therapy/*genetics, *Chromosome Deletion, Chromosomes, Human, Pair 1/*genetics, Dacarbazine/*analogs & derivatives/*therapeutic use, Female, Humans, Loss of Heterozygosity, Magnetic Resonance Imaging, Male, Middle Aged, Oligodendroglioma/*drug therapy/*genetics.



50. F. Laigle-Donadey, N. Martin-Duverneuil, J. Lejeune, E. Criniere, L. Capelle, H. Duffau, P. Cornu, P. Broet, M. Kujas, K. Mokhtari, A. Carpentier, M. Sanson, K. Hoang-Xuan, J. Thillet, and J. Y. Delattre. Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology, 63(12):2360-2, 2004. Note: Comparative StudyJournal ArticleReviewUnited States. [WWW] Keyword(s): Adult, Aged, Brain Neoplasms/*genetics/pathology/*radiography, Cerebral Cortex/pathology/radiography, Chromosomes, Human, Pair 1/*genetics, Female, Humans, *Loss of Heterozygosity, Male, Microsatellite Repeats, Middle Aged, Oligodendroglioma/*genetics/pathology/*radiography, Retrospective Studies, Supratentorial Neoplasms/genetics/pathology/radiography.



51. P. Leuraud, E. Dezamis, L. Aguirre-Cruz, S. Taillibert, J. Lejeune, E. Robin, K. Mokhtari, A. L. Boch, P. Cornu, J. Y. Delattre, and M. Sanson. Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg, 100(2):303-9, 2004. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adult, Aged, Aged, 80 and over, Chromosome Mapping, Disease Progression, Female, Humans, Loss of Heterozygosity/*genetics, Male, Meningeal Neoplasms/*genetics, Meningioma/*genetics, Middle Aged, Neoplasm Recurrence, Local/*genetics, Predictive Value of Tests, Prognosis, Telomerase/*genetics/physiology.



52. P. Leuraud, L. Taillandier, J. Medioni, L. Aguirre-Cruz, E. Criniere, Y. Marie, M. Kujas, J. L. Golmard, A. Duprez, J. Y. Delattre, M. Sanson, and M. F. Poupon. Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res, 64(13):4648-53, 2004. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Animals, Antineoplastic Agents, Alkylating/*pharmacology, Carboplatin/pharmacology, Carmustine/pharmacology, *Chromosome Aberrations, Dacarbazine/*analogs & derivatives/pharmacology, Glioblastoma/*drug therapy/*genetics/pathology, Humans, Ifosfamide/pharmacology, Loss of Heterozygosity, Mice, Mice, Nude, Mutation, Oligodendroglioma/*drug therapy/*genetics/pathology, Xenograft Model Antitumor Assays.



53. G. Noel, C. N. Ben Ammar, L. Feuvret, C. A. Valery, P. Cornu, G. Boisserie, J. M. Simon, D. Hasboun, B. Tep, J. Y. Delattre, M. Sanson, F. Baillet, and J. J. Mazeron. [Results of salvage stereotactic radiosurgery in 14 patients with grade III or IV gliomas]. Rev Neurol (Paris), 160(5 Pt 1):539-45, 2004. Note: English AbstractJournal ArticleFrance. [WWW] Keyword(s): Brain Neoplasms/pathology/*surgery, Female, Follow-Up Studies, Glioma/pathology/*surgery, Humans, Karnofsky Performance Status, Male, Middle Aged, Necrosis, Neoplasm Recurrence, Local, Prognosis, Radiation Dosage, *Radiosurgery/adverse effects, *Salvage Therapy, Survival Analysis.



54. M. Sanson, S. Cartalat-Carel, S. Taillibert, M. Napolitano, L. Djafari, J. Cougnard, H. Gervais, F. Laigle, A. Carpentier, K. Mokhtari, L. Taillandier, O. Chinot, H. Duffau, J. Honnorat, K. Hoang-Xuan, and J. Y. Delattre. Initial chemotherapy in gliomatosis cerebri. Neurology, 63(2):270-5, 2004. Note: ANOCEF groupClinical TrialComparative StudyControlled Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols/administration &, dosage/adverse effects/*therapeutic use, Astrocytoma/drug therapy/radiotherapy, Brain Neoplasms/*drug therapy/pathology/radiotherapy, Combined Modality Therapy, Cranial Irradiation, Dacarbazine/adverse effects/*analogs & derivatives/*therapeutic use, Disease Progression, Disease-Free Survival, Drug Administration Schedule, Female, Hematologic Diseases/chemically induced, Humans, Karnofsky Performance Status, Lomustine/administration & dosage/adverse effects, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasms, Neuroepithelial/*drug therapy/pathology/radiotherapy, Oligodendroglioma/drug therapy/radiotherapy, Procarbazine/administration & dosage/adverse effects, Survival Analysis, Treatment Outcome, Vincristine/administration & dosage/adverse effects.



55. M. Sanson, J. Thillet, and K. Hoang-Xuan. Molecular changes in gliomas. Curr Opin Oncol, 16(6):607-13, 2004. Note: Journal ArticleReviewUnited States. [WWW] Keyword(s): Antineoplastic Agents/therapeutic use, Central Nervous System Neoplasms/diagnosis/*genetics/therapy, Epidermal Growth Factor/antagonists & inhibitors, Glioma/diagnosis/*genetics/therapy, Humans, Neovascularization, Pathologic/genetics, Quinazolines/therapeutic use, Tumor Markers, Biological.



56. O. Trouillard, L. Aguirre-Cruz, K. Hoang-Xuan, Y. Marie, J. Y. Delattre, and M. Sanson. Parental 19q loss and PEG3 expression in oligodendrogliomas. Cancer Genet Cytogenet, 151(2):182-3, 2004. Note: LetterResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Brain Neoplasms/*genetics, *Chromosome Deletion, *Chromosomes, Human, Pair 19, *Genomic Imprinting, Humans, Oligodendroglioma/*genetics, *Protein Kinases, Proteins/*genetics, *Transcription Factors.



57. J. S. Guillamo, A. Creange, C. Kalifa, J. Grill, D. Rodriguez, F. Doz, S. Barbarot, M. Zerah, M. Sanson, S. Bastuji-Garin, and P. Wolkenstein. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain, 126(Pt 1):152-60, 2003. Note: Reseau NF FranceJournal ArticleMulticenter StudyEnglanda journal of neurology. [WWW] Keyword(s): Adolescent, Adult, Age of Onset, Astrocytoma/*mortality/pathology/therapy, Brain Stem Neoplasms/mortality/pathology/therapy, Central Nervous System Neoplasms/*mortality/pathology/therapy, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Neurofibromatosis 1/*mortality/pathology/therapy, Prognosis, Proportional Hazards Models, Retrospective Studies, Survival Analysis.



58. P. Leuraud, L. Aguirre-Cruz, K. Hoang-Xuan, E. Criniere, M. L. Tanguy, J. L. Golmard, M. Kujas, J. Y. Delattre, and M. Sanson. Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1. Neurology, 60(11):1820-2, 2003. Note: Journal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Chromosome Mapping, *Chromosomes, Human, Pair 10, Glioma/enzymology/*genetics, Humans, *Loss of Heterozygosity, Telomerase/*metabolism.



59. P. Leuraud, L. Taillandier, L. Aguirre-Cruz, J. Medioni, E. Criniere, Y. Marie, A. M. Dutrillaux, M. Kujas, A. Duprez, J. Y. Delattre, M. F. Poupon, and M. Sanson. Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice. Br J Cancer, 89(12):2327-32, 2003. Note: Journal ArticleResearch Support, Non-U.S. Gov'tEngland. [WWW] Keyword(s): Adult, Aged, Animals, Cell Division/*genetics, Central Nervous System Neoplasms/*genetics/*pathology, Female, Genes, Tumor Suppressor/physiology, Genes, erbB-1/genetics, Genes, p53/genetics, Glioma/*genetics/*pathology, Humans, Loss of Heterozygosity/genetics, Male, Mice, Mice, Nude, Middle Aged, *Models, Animal, Mutation/*genetics, Neoplasm Transplantation, PTEN Phosphohydrolase, Phosphoric Monoester Hydrolases/genetics, Proto-Oncogenes/genetics, Telomerase/genetics, Tumor Suppressor Proteins/genetics.



60. E. Louis, C. Cret, J. Poirier, P. Cornu, N. Martin-Duverneuil, J. Y. Delattre, and M. Sanson. Intra-cerebral schwannoma simulating glioma. J Neurooncol, 64(3):279-82, 2003. Note: Case ReportsJournal ArticleNetherlands. [WWW] Keyword(s): Biopsy, Brain Neoplasms/*pathology/radiotherapy/surgery, Diagnosis, Differential, Female, Frontal Lobe/pathology/radiation effects/surgery, Glioma/*pathology/radiotherapy/surgery, Humans, Magnetic Resonance Imaging, Middle Aged, Neurilemmoma/*pathology/radiotherapy/surgery, Treatment Failure, Treatment Outcome.



61. E. Louis, F. Keime-Guibert, J. Y. Delattre, and M. Sanson. Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. Neurology, 60(1):151, 2003. Note: Case ReportsJournal ArticleUnited States. [WWW] Keyword(s): Adult, Antineoplastic Combined Chemotherapy Protocols/administration &, dosage/*therapeutic use, Biopsy, Brain Neoplasms/*diagnosis/*drug therapy, Corpus Callosum/pathology, Frontal Lobe/pathology, Humans, Lomustine/administration & dosage, Magnetic Resonance Imaging, Male, Neoplasms, Neuroepithelial/complications/*diagnosis/*drug therapy, Oligodendroglia/*pathology, Parietal Lobe/pathology, Procarbazine/administration & dosage, Remission Induction, Seizures/etiology, Tomography, X-Ray Computed, Treatment Outcome, Vincristine/administration & dosage.



62. M. Sanson, L. Aguirre-Cruz, S. Cartalat-Carel, and K. Hoang-Xuan. Oligodendrogliomas: an update on basic and clinical research. Curr Neurol Neurosci Rep, 3(3):223-8, 2003. Note: Journal ArticleResearch Support, Non-U.S. Gov'tReviewUnited States. [WWW] Keyword(s): Animals, Biomedical Research, Brain Neoplasms/classification/*genetics/therapy, Chromosomes, Human, Pair 1/genetics, Chromosomes, Human, Pair 19, Gene Expression Regulation, Neoplastic/*genetics, Humans, Loss of Heterozygosity/genetics, Oligodendroglioma/classification/*genetics/therapy, *Tumor Markers, Biological/analysis.

This material is presented to ensure timely dissemination of scholarly and technical work. Copyright and all rights therein are retained by authors or by other copyright holders. All person copying this information are expected to adhere to the terms and constraints invoked by each author's copyright. In most cases, these works may not be reposted without the explicit permission of the copyright holder.

Les documents contenus dans ces répertoires sont rendus disponibles par les auteurs qui y ont contribué en vue d'assurer la diffusion à temps de travaux savants et techniques sur une base non-commerciale. Les droits de copie et autres droits sont gardés par les auteurs et par les détenteurs du copyright, en dépit du fait qu'ils présentent ici leurs travaux sous forme électronique. Les personnes copiant ces informations doivent adhérer aux termes et contraintes couverts par le copyright de chaque auteur. Ces travaux ne peuvent pas être rendus disponibles ailleurs sans la permission explicite du détenteur du copyright.

This document was translated from BibT_EX by bibtex2html